Compile Data Set for Download or QSAR
maximum 50k data
Found 43 Enz. Inhib. hit(s) with all data for entry = 831
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293963(US10106552, Compound 38)
Affinity DataIC50:  300nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293953(US10106552, Compound 28)
Affinity DataIC50:  400nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293961(US10106552, Compound 36)
Affinity DataIC50:  400nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293965(US10106552, Compound 40)
Affinity DataIC50:  400nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293960(US10106552, Compound 35)
Affinity DataIC50:  400nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293966(US10106552, Compound 41)
Affinity DataIC50:  500nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293954(US10106552, Compound 29)
Affinity DataIC50:  700nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293950(US10106552, Compound 25)
Affinity DataIC50:  800nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293959(US10106552, Compound 34)
Affinity DataIC50:  800nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293962(US10106552, Compound 37)
Affinity DataIC50:  900nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293968(US10106552, Compound 43)
Affinity DataIC50:  900nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293943(US10106552, Compound 18)
Affinity DataIC50:  900nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293935(US10106552, Compound 10)
Affinity DataIC50:  1.00E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293951(US10106552, Compound 26)
Affinity DataIC50:  1.00E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293927(US10106552, Compound 2)
Affinity DataIC50:  1.10E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293958(US10106552, Compound 33)
Affinity DataIC50:  1.10E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293944(US10106552, Compound 19)
Affinity DataIC50:  1.10E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293942(US10106552, Compound 17)
Affinity DataIC50:  1.10E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293931(US10106552, Compound 6)
Affinity DataIC50:  1.20E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293949(US10106552, Compound 24)
Affinity DataIC50:  1.40E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293964(US10106552, Compound 39)
Affinity DataIC50:  1.40E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293952(US10106552, Compound 27)
Affinity DataIC50:  1.50E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293932(US10106552, Compound 7)
Affinity DataIC50:  1.60E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293948(US10106552, Compound 23)
Affinity DataIC50:  2.00E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293946(US10106552, Compound 21)
Affinity DataIC50:  2.00E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293945(US10106552, Compound 20)
Affinity DataIC50:  2.20E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293934(US10106552, Compound 9)
Affinity DataIC50:  2.40E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293940(US10106552, Compound 15)
Affinity DataIC50:  2.50E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293926(US10106552, Compound 1)
Affinity DataIC50:  2.70E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293967(US10106552, Compound 42)
Affinity DataIC50:  3.10E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293955(US10106552, Compound 30)
Affinity DataIC50:  3.40E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293956(US10106552, Compound 31)
Affinity DataIC50:  3.50E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293957(US10106552, Compound 32)
Affinity DataIC50:  3.80E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293941(US10106552, Compound 16)
Affinity DataIC50:  4.60E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293933(US10106552, Compound 8)
Affinity DataIC50:  4.70E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293937(US10106552, Compound 12)
Affinity DataIC50:  5.00E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293947(US10106552, Compound 22)
Affinity DataIC50:  6.00E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293930(US10106552, Compound 5)
Affinity DataIC50:  6.00E+3nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293936(US10106552, Compound 11)
Affinity DataIC50:  2.30E+4nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293938(US10106552, Compound 13)
Affinity DataIC50:  3.10E+4nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293939(US10106552, Compound 14)
Affinity DataIC50:  5.02E+6nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293929(US10106552, Compound 4)
Affinity DataIC50:  1.00E+7nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEukaryotic elongation factor 2 kinase(Homo sapiens (Human))
Longevica Pharmaceuticals

US Patent
LigandPNGBDBM293928(US10106552, Compound 3)
Affinity DataIC50:  1.00E+7nMAssay Description:To determine the IC50 of compounds of the invention, recombinant eEF2K was diluted in an assay buffer in the presence of calmodulin, a calcium-bindin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent